Research programme: next-generation epothilone analogues - Kosan
Latest Information Update: 04 Nov 2017
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Kosan Biosciences
- Class Epothilones
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 27 Jun 2008 Kosan Biosciences has been acquired by Bristol-Myers Squibb
- 30 Oct 2007 Roche terminates its worldwide licence for next-generation epothilone analogues